Immunoprecise Antibodies Ltd Stock Other OTC
Equities
CA87588T1030
Pharmaceuticals
Sales 2024 * | 24.59M 17.92M | Sales 2025 * | 29.82M 21.74M | Capitalization | 37.82M 27.57M |
---|---|---|---|---|---|
Net income 2024 * | -12M -8.75M | Net income 2025 * | -9M -6.56M | EV / Sales 2024 * | 1.54 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.27 x |
P/E ratio 2024 * |
-2.98
x | P/E ratio 2025 * |
-4.03
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.41% |
Latest transcript on Immunoprecise Antibodies Ltd
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 18-02-20 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 23-09-28 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 23-09-04 |
Jennifer Bath
CEO | Chief Executive Officer | - | 18-02-20 |
1st Jan change | Capi. | |
---|---|---|
+2.52% | 92.1B | |
-3.16% | 37.92B | |
-12.17% | 32.97B | |
+75.35% | 27.92B | |
-11.32% | 16.14B | |
+0.19% | 14.1B | |
-11.18% | 11.66B | |
+171.57% | 10.29B | |
-50.45% | 9.99B |